Twist Bioscience Corp. Stock News

During the last session, Twist Bioscience Corporation (NASDAQ:TWST)’s traded shares were 0.67 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $43.79, reflecting an intraday loss of -11.28% or -$5.57. The 52-week high for the TWST share is $150.25, that puts it down … Twist Bioscience Corporation (NASDAQ: TWST)’s -9.06% Loss This Week Just Tells Us Something New Read More »

Twist Biosciences (TWST) will collaborate with Kriya Therapeutics to discover antibodies delivered using adeno-associated viral gene therapy for oncology applications.

SOUTH SAN FRANCISCO, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology

The C2intelligence Platform enables custom, cost-effective, efficient, automatic, and globally accessible cancer data management and real-time monitoring. SAN ANTONIO , Feb. 24, 2022 /PRNewswire/ -- Based on a recent industry analysis, Frost & Sullivan recognizes C2i Genomics with the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award. The company improves cancer monitoring through its globally accessible digital cancer monitoring system. Based on the next-generation sequencing (NGS) technology, the system allows whole genome sequencing (WGS) to occur quickly prior to analyzing large volumes of data generated. WGS, unlike medical scans or regular blood tests, provides insights and details at the genomic level. It detects richer genomic signatures from circulating tumor DNA (ctDNA) and covers all genes, expanding the scope to provide information based on larger sequenced regions. C2i Genomics C2i Genomics'' scalable software-as-a-service (SaaS) solution analyzes the WGS for high-precision, personalized cancer management to meet existing cancer monitoring shortcomings.

Twist Bioscience Corporation (NASDAQ: TWST ) has priced its upsized underwritten public offering of 4.5 million at $55.00 per share , with gross proceeds of approximately $250 million. Earlier, the Company had announced the public offering of $200 million . The Offer price Full story available on Benzinga.com

Twist Bioscience (TWST) has priced an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00/share for an expected gross

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share. The gross proceeds of the offering to Twist before deducting the underwriting discount and commissions and estimated offering expen

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 8:00 a.m. Eastern Time. The presentation will be webcast li

Twist Bioscience (TWST) announced a proposed $200M underwritten public offering of shares.TWST intends to grant the underwriters a 30-day option to purchase up to $30M of…

Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe C2i to integrate Twist’s library preparation kits into minimal residual disease workflow NEW YORK &

Twist Bioscience Corp (NASDAQ: TWST ) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development. Replicons are synthetic viral RNA molecules that mimic viruses in their ability to replicate but have been engineered to remove the portion … Full story available on Benzinga.com